| scholarly article | Q13442814 |
| P50 | author | Dmitri B. Kirpotin | Q55345327 |
| P2093 | author name string | Gregory P Adams | |
| Yu Zhou | |||
| James D Marks | |||
| Hao Zou | |||
| Daryl C Drummond | |||
| Mark E Hayes | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Yeast recombination: the association between double-strand gap repair and crossing-over | Q28265497 | ||
| A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs | Q28285226 | ||
| Phosphorus assay in column chromatography | Q29614973 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Applications of high efficiency lithium acetate transformation of intact yeast cells using single-stranded nucleic acids as carrier | Q29618081 | ||
| Toward selection of internalizing antibodies from phage libraries | Q30650054 | ||
| Phage versus phagemid libraries for generation of human monoclonal antibodies. | Q30712277 | ||
| The use of scFv-displaying yeast in mammalian cell surface selections | Q30796115 | ||
| By-passing immunization. Human antibodies from V-gene libraries displayed on phage | Q30831419 | ||
| Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies | Q30841593 | ||
| Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library | Q30882235 | ||
| Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries | Q30890428 | ||
| Selection of tumor-specific internalizing human antibodies from phage libraries | Q30914112 | ||
| Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity | Q30923970 | ||
| Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose | Q30945361 | ||
| Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library | Q30982238 | ||
| By-passing immunization: building high affinity human antibodies by chain shuffling | Q30988323 | ||
| Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis | Q31104590 | ||
| Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens | Q32062847 | ||
| Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. | Q33218388 | ||
| Isolation of scFvs to in vitro produced extracellular domains of EGFR family members | Q33231107 | ||
| Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. | Q33784378 | ||
| EGF mutant receptor vIII as a molecular target in cancer therapy | Q33950534 | ||
| Comparative properties and methods of preparation of lipid vesicles (liposomes). | Q34275078 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| Arming antibodies: prospects and challenges for immunoconjugates | Q34449555 | ||
| Developing inhibitors of the epidermal growth factor receptor for cancer treatment. | Q35157038 | ||
| Ligand-targeted liposomal anticancer drugs | Q35157616 | ||
| Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer | Q35177848 | ||
| Epidermal growth factor receptor: a promising target in solid tumours | Q35650434 | ||
| Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies | Q35669133 | ||
| Development of ligand-targeted liposomes for cancer therapy | Q35842511 | ||
| Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection | Q36791789 | ||
| Phage libraries--a new route to clinically useful antibodies | Q36807332 | ||
| Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections | Q36849268 | ||
| A model system for detection and isolation of a tumor cell surface antigen using antibody phage display | Q36858109 | ||
| In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library | Q36891713 | ||
| Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification | Q40421390 | ||
| Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes | Q40427954 | ||
| Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme | Q40512036 | ||
| Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells | Q40595415 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. | Q40829903 | ||
| Determination of the binding affinity of an anti-CD34 single-chain antibody using a novel, flow cytometry based assay | Q41126558 | ||
| Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. | Q42812982 | ||
| Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). | Q43430617 | ||
| Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. | Q44480735 | ||
| Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery | Q46059342 | ||
| Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo | Q46067245 | ||
| Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis | Q46498459 | ||
| Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer | Q46502913 | ||
| Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy | Q46537704 | ||
| Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity | Q46556543 | ||
| Glioblastoma multiforme and the epidermal growth factor receptor | Q46799624 | ||
| Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. | Q50904345 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma | Q73783191 | ||
| High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules | Q74020325 | ||
| Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies | Q74150880 | ||
| Monoclonal antibody therapy of cancer | Q81189032 | ||
| Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers | Q82808514 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| antibody | Q79460 | ||
| P304 | page(s) | 934-947 | |
| P577 | publication date | 2007-05-10 | |
| P1433 | published in | Journal of Molecular Biology | Q925779 |
| P1476 | title | Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells | |
| P478 | volume | 371 |
| Q50032634 | A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. |
| Q33855309 | A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors |
| Q33688219 | A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo |
| Q34692050 | A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro |
| Q53100671 | Adding Functions to Biomaterial Surfaces through Protein Incorporation. |
| Q36028047 | Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice |
| Q39720680 | An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors |
| Q35121107 | An evolved Mxe GyrA intein for enhanced production of fusion proteins |
| Q92886775 | Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models |
| Q34154532 | CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells |
| Q38227494 | Cancer active targeting by nanoparticles: a comprehensive review of literature. |
| Q30620660 | Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting. |
| Q37668316 | Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents |
| Q37993466 | Challenges in development of targeted liposomal therapeutics |
| Q27665886 | Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic |
| Q37765187 | Clinical developments in nanotechnology for cancer therapy |
| Q39158242 | Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models |
| Q36043818 | Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor |
| Q38067265 | Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. |
| Q28749660 | Development of genetically engineered human sperm immunocontraceptives |
| Q47209586 | Discovery of internalizing antibodies to basal breast cancer cells |
| Q34114794 | Discovery of internalizing antibodies to tumor antigens from phage libraries |
| Q34197322 | Doxorubicin-conjugated chimeric polypeptide nanoparticles that respond to mild hyperthermia. |
| Q27013001 | EGF receptor-targeted nanocarriers for enhanced cancer treatment |
| Q36413263 | Effect of ligand density, receptor density, and nanoparticle size on cell targeting |
| Q35897306 | Efficient construct of a large and functional scFv yeast display library derived from the ascites B cells of ovarian cancer patients by three-fragment transformation-associated recombination. |
| Q64882409 | Fab is the most efficient format to express functional antibodies by yeast surface display. |
| Q37591930 | GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation |
| Q34404779 | Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies |
| Q33695432 | Internalizing Cancer Antibodies from Phage Libraries Selected on Tumor Cells and Yeast-Displayed Tumor Antigens |
| Q33326086 | Isolation of human single chain variable fragment antibodies against specific sperm antigens for immunocontraceptive development |
| Q56977745 | Ligand Density and Nanoparticle Clustering Cooperate in the Multivalent Amplification of Epidermal Growth Factor Receptor Activation |
| Q30354223 | Magnetic Nanoparticle Facilitated Drug Delivery for Cancer Therapy with Targeted and Image-Guided Approaches |
| Q33666994 | Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles |
| Q33588489 | Mining human antibody repertoires |
| Q30612000 | Molecular imaging of cancer cells using a bacteriophage-based 129Xe NMR biosensor |
| Q36213754 | N-Terminal labeling of filamentous phage to create cancer marker imaging agents |
| Q29615628 | Nanoparticle therapeutics: an emerging treatment modality for cancer |
| Q91831250 | Nanoparticle-Based Contrast Agents for 129Xe HyperCEST NMR and MRI Applications |
| Q28067824 | Optical imaging probes in oncology |
| Q92860814 | Perlecan-targeted nanoparticles for drug delivery to triple-negative breast cancer |
| Q33849788 | Phage display and molecular imaging: expanding fields of vision in living subjects |
| Q35162058 | Photothermolysis mediated by gold nanorods modified with EGFR monoclonal antibody induces Hep-2 cells apoptosis in vitro and in vivo |
| Q35052025 | Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. |
| Q33560821 | Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8. |
| Q30890447 | Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma |
| Q37337213 | Quantum dot-based nanoprobes for in vivo targeted imaging |
| Q34580658 | Rapid optimization and prototyping for therapeutic antibody-like molecules |
| Q99728030 | SERRS multiplexing with multivalent nanostructures for the identification and enumeration of epithelial and mesenchymal cells |
| Q54112592 | ScFvs as Allosteric Inhibitors of VEGFR-2: Novel Tools to Harness VEGF Signaling. |
| Q91931124 | Selection and characterization of FcεRI phospho-ITAM specific antibodies |
| Q34280931 | Selection and characterization of cell binding and internalizing phage antibodies |
| Q36765663 | Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging |
| Q35764163 | Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach |
| Q28754430 | Status of contraceptive vaccines |
| Q42033562 | TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS |
| Q22255481 | Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. |
| Q39451814 | Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles |
| Q37712977 | Targeted small interfering RNA-immunoliposomes as a promising therapeutic agent against highly pathogenic Avian Influenza A (H5N1) virus infection |
| Q38050063 | Targeting and delivery of platinum-based anticancer drugs |
| Q33465023 | Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8. |
| Q50579985 | The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. |
| Q43564347 | The effect of dual ligand-targeted micelles on the delivery and efficacy of poorly soluble drug for cancer therapy |
| Q38328927 | The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. |
| Q34698633 | Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery |
| Q38658279 | Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies |
| Q35671544 | Using engineered single-chain antibodies to correlate molecular binding properties and nanoparticle adhesion dynamics |
| Q33870581 | Vaccine for human contraception targeting sperm Izumo protein and YLP12 dodecamer peptide |
| Q37564106 | pH-Responsive Theranostic Polymer-Caged Nanobins (PCNs): Enhanced Cytotoxicity and T1 MRI Contrast by Her2-Targeting. |